Cancers (Dec 2020)

Defining the Inflammatory Plasma Proteome in Pediatric Hodgkin Lymphoma

  • Jennifer E. Agrusa,
  • Brooks P. Scull,
  • Harshal A. Abhyankar,
  • Howard Lin,
  • Nmazuo W. Ozuah,
  • Rikhia Chakraborty,
  • Olive S. Eckstein,
  • Nitya Gulati,
  • Elmoataz Abdel Fattah,
  • Nader K. El-Mallawany,
  • Rayne H. Rouce,
  • ZoAnn E. Dreyer,
  • Julienne Brackett,
  • Judith F. Margolin,
  • Joseph Lubega,
  • Terzah M. Horton,
  • Catherine M. Bollard,
  • M. Monica Gramatges,
  • Kala Y. Kamdar,
  • Kenneth L. McClain,
  • Tsz-Kwong Man,
  • Carl E. Allen

DOI
https://doi.org/10.3390/cancers12123603
Journal volume & issue
Vol. 12, no. 12
p. 3603

Abstract

Read online

Hodgkin lymphoma (HL) histopathology is characterized by rare malignant Reed–Sternberg cells among an inflammatory infiltrate. We hypothesized that characteristics of inflammation in pediatric HL lesions would be reflected by the levels of inflammatory cytokines or chemokines in pre-therapy plasma of children with HL. The study objectives were to better define the inflammatory pre-therapy plasma proteome and identify plasma biomarkers associated with extent of disease and clinical outcomes in pediatric HL. Pre-therapy plasma samples were obtained from pediatric subjects with newly diagnosed HL and healthy pediatric controls. Plasma concentrations of 135 cytokines/chemokines were measured with the Luminex platform. Associations between protein concentration and disease characteristics were determined using multivariate permutation tests with false discovery control. Fifty-six subjects with HL (mean age: 13 years, range 3–18) and 47 controls were analyzed. The cytokine/chemokine profiles of subjects with HL were distinct from controls, and unique cytokines/chemokines were associated with high-risk disease (IL-10, TNF-α, IFN-γ, IL-8) and slow early response (CCL13, IFN-λ1, IL-8). TNFSF10 was significantly elevated among those who ultimately relapsed and was significantly associated with worse event-free survival. These biomarkers could be incorporated into biologically based risk stratification to optimize outcomes and minimize toxicities in pediatric HL.

Keywords